Epidemiology

Adenoma characteristics associated with post-polypectomy proximal colon cancer incidence: a retrospective cohort study

Rhea Harewood ^{1,2^M}, Kate Wooldrage², Emma C. Robbins², James Kinross ³, Christian von Wagner⁴ and Amanda J. Cross^{1,2}

© The Author(s) 2022

BACKGROUND: Colorectal cancer (CRC) screening is less effective at reducing cancer incidence in the proximal colon compared to the distal colorectum. We aimed to identify adenoma characteristics associated with proximal colon cancer (PCC).

METHODS: Endoscopy and pathology data for patients with ≥ 1 adenoma detected at baseline colonoscopy were obtained from 17 UK hospitals between 2001 and 2010. Multivariable Cox regression models were used to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (Cls) for PCC, and, for comparison, distal CRC incidence, by adenoma characteristics.

RESULTS: Among 18,431 patients, 152 and 105 developed PCC and distal CRC, respectively, over a median follow-up of 9.8 years. Baseline adenoma characteristics positively associated with PCC incidence included number (≥3 vs. < 3: aHR 2.10, 95% CI:

1.42–3.09), histology (tubulovillous/villous vs. tubular: aHR 1.61, 95% CI: 1.10–2.35) and location (any proximal vs. distal only: aHR 1.70, 95% CI: 1.20–2.42), for which there was borderline evidence of heterogeneity by subsite (p = 0.055). Adenoma dysplasia (high vs. low grade) was associated with distal CRC (aHR 2.42, 95% CI: 1.44–4.04), but not PCC (p-heterogeneity = 0.023).

CONCLUSIONS: Baseline adenoma number, histology and proximal location were independently associated with PCC and may be important to identify patients at higher risk for post-polypectomy PCC.

British Journal of Cancer; https://doi.org/10.1038/s41416-022-01719-4

BACKGROUND

The incidence of colorectal cancer (CRC) is higher in individuals with a personal history of adenomas [1, 2]. Reductions in incidence have been achieved through colonoscopies to identify and remove adenomas, known precursors, followed by post-polypectomy surveillance colonoscopy to prevent the progression of missed, incompletely resected or de novo adenomas to malignancy. These methods have been particularly effective at preventing cancers in the distal colon and rectum, but unfortunately have demonstrated a weaker protective effect in the proximal colon, with a greater propensity for adenoma recurrence [3–6] and post-colonoscopy CRC [7–9] in this subsite.

One reason for the lower level of protection offered by colonoscopy against proximal colon cancer is likely to be the failure to identify those patients at higher risk for proximal colon cancer after polypectomy, who would benefit from referral to colonoscopy surveillance. In the case where such patients are identified, failure to provide surveillance at optimum intervals could be another contributing factor.

There are few studies reporting associations between adenoma characteristics and an increased incidence of long-term all-site CRC. A retrospective cohort study [10] in a UK population with adenomas detected at baseline colonoscopy reported associations with all-site CRC for adenoma histology and polyp location in low-risk (1–2 small [<10 mm] adenomas at baseline) and intermediate-risk patients (3–4 small adenomas, or 1–2 adenomas with \geq 1 large [\geq 10 mm] adenoma at baseline) and for adenoma dysplasia in intermediate- and high-risk patients (\geq 5 small adenomas, or \geq 3 adenomas with \geq 1 large adenoma at baseline). Similarly, a study in the US [11] reported associations between the number, size, histology and dysplasia of baseline adenomas and all-site CRC, with another analysis of three large prospective US cohorts finding somewhat similar results when compared to those without polyps [12]. A multi-centre population-based cohort study in Poland also found that among patients with adenomas detected, adenoma size (\geq 20 mm) and dysplasia were independent risk factors for all-site CRC [13].

Findings of associations between adenoma characteristics and CRC risk has been important for informing criteria for postpolypectomy risk stratification and surveillance guidelines [14–16]. However, considering the growing evidence of heterogeneity in the development of CRC by subsite, it is important to determine whether associations between adenoma characteristics and CRC differ by subsite to better understand the lower effectiveness of colonoscopy at reducing the incidence of cancer in the proximal colon compared to distal colon and rectal subsites [17–22]. This study aimed to identify baseline adenoma characteristics associated with incident proximal colon cancer in a large cohort of

Received: 19 August 2021 Revised: 3 January 2022 Accepted: 25 January 2022 Published online: 11 February 2022

Check for updates

¹Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. ²Cancer Screening and Prevention Research Group (CSPRG), Department of Surgery and Cancer, Imperial College London, London, UK. ³Department of Surgery and Cancer, Imperial College London, London, UK. ⁴Research Department of Behavioural Science and Health, University College London, London, UK. ^{Ke}email: r.harewood18@imperial.ac.uk

2

patients referred for colonoscopy and followed up for a median of ten years.

METHODS

Data source

The All Adenomas study is a retrospective cohort study investigating longterm CRC incidence and the effectiveness of colonoscopic surveillance in preventing CRC among patients with adenomas. Detailed information on the study and its methodology are described elsewhere [23, 24]. Briefly, a cohort of ~250,000 patients was identified from routinely collected data from 17 UK hospitals, all known to have 6 years or more of electronic endoscopy and pathology data prior to the start of the study in 2006.

Endoscopy databases were searched for patients who underwent a lower gastrointestinal endoscopy prior to 31 December 2010. Pathology databases were searched using Systematized Nomenclature of Medicine (SNOMED) or, where not available, Systematized Nomenclature of Pathology (SNOP) codes and keywords were used to identify and classify lesions occurring in the colorectum. Automatic procedures were used to link endoscopy and corresponding pathology reports based on hospital number, name and date of birth. Manual inspection was performed to highlight any linkage issues and data were re-extracted when necessary [23].

A baseline visit was defined as the first examination at which an adenoma was detected (this may not have been a patient's first endoscopy) and any following consecutive examinations, usually performed within 11 months, required in order to completely examine the colorectum and remove all detected adenomas. Subsequent colonic examinations were grouped into surveillance visits in a similar manner [23, 24].

Patients were included in analyses if they had a colonoscopy performed during which at least one adenoma was detected. Patients were excluded from analyses if they did not have a colonoscopy at baseline. We also excluded those with conditions which put them at a higher risk for future CRC and therefore not representative of the general population at risk. This included those with prevalent CRC, a history of inflammatory bowel disease or colitis, polyposis, juvenile polyps, hamartomatous polyps, Lynch syndrome, a family history of familial adenomatous polyposis or volvulus at baseline. Patients with a bowel resection at or before baseline or a record of colorectal carcinoma in situ from national sources more than three years prior to baseline, those with a missing endoscopy date (precluding determination of follow-up time) and those lost to follow-up (i.e. those who emigrated or could not be identified in external data sources and did not have a surveillance visit) were also excluded [23, 24]. Additionally, to ensure that we included only patients in whom the entire colorectum was examined, we excluded patients whose baseline colonoscopy was either incomplete (scope did not reach the caecum) or was of unknown completeness. We also excluded patients with a baseline colonoscopy examination prior to 2001 when UK endoscopic quality criteria were introduced. Due to small percentages of missingness for the main exposure variables (adenoma size 2.1%, adenoma histology 4.5%, adenoma dysplasia 2.4% and adenoma location 2.0%), patients missing data for any of the adenoma characteristics under study were excluded from analyses.

Exposures at baseline colonoscopy

The following adenoma characteristics were examined at baseline: adenoma number (< 3, \geq 3); adenoma size (diameter < 10 mm, \geq 10 mm); adenoma histology (tubular, tubulovillous or villous); adenoma grade of dysplasia (low-grade dysplasia, high-grade dysplasia) and adenoma location (distal [between the anus and descending colon] or proximal [between the splenic flexure and caecum]). Categories for analysis were based on previous literature [2, 14], distributions in the data and taking consideration of past and current surveillance criteria [14, 25]. For individuals who had an adenoma seen at multiple endoscopy examinations during the baseline visit, summary values were assigned for each adenoma using previously published algorithms [23]. Patient and examination characteristics were also collected, including sex, age, year of examination, bowel preparation quality (excellent or good, satisfactory, poor), the presence of hyperplastic polyps (yes, no), length of the baseline visit (1 day, 2 days-3 months, >3-6 months, >6 months) and the centre where the examination was performed.

Baseline adenoma and examination quality characteristics were defined for each patient by assigning adenoma size as the largest diameter, histology as the highest degree of villousness, dysplasia as the highest grade and bowel preparation as the highest quality preparation reported.

Outcome

Data on deaths and CRC diagnoses were obtained from NHS Digital up to 31 December 2017, and from National Health Service Central Register and National Services Scotland up to 31 May 2016. CRC diagnoses were also obtained from hospital data and were compared with those from external sources and duplicates removed. Methods used to resolve discrepancies between data sources were previously described [23]. Briefly, all CRC diagnoses from external sources and those pathologically confirmed by hospital data were counted as cancer, even if not reported by national sources for the latter. Suspected cancers reported at endoscopy but not confirmed by pathology or the national data sources were not counted as a case of cancer. Cancers were excluded if there was strong evidence they developed from an incompletely resected adenoma at baseline. These cancers were defined as those diagnose in the same or adjacent segment of the colorectum as a large (\geq 15 mm) baseline adenoma seen at least twice in the 5 years before the cancer diagnosis; this was done in line with previous analyses in this dataset.

CRC was defined as adenocarcinoma of the colorectum. Proximal colon cancer included cancer between the caecum and splenic flexure (International Classification of Diseases for Oncology, third edition [ICD-O-3] codes C18.0–C18.5). Distal CRC included cancer between the descending colon and the anus (ICD-O-3 codes C18.6–C18.7; C19; C20; C21). Three patients were diagnosed with both proximal and distal cancer (one with both cancers diagnosed on the same date, two with proximal cancer diagnosed first and distal CRC diagnosed 7 months later in one and 15 months later in the other) and the proximal colon cancer was prioritised for analysis as proximal colon cancer was the primary focus of these analyses. Cancers, except those in the appendix or anus, with unknown morphology were assumed to be adenocarcinomas [23].

Statistical analyses

The distribution of baseline patient and examination characteristics were compared within the population and by exposure variables.

Follow-up time began at the date of the last endoscopy examination in the baseline visit. Patients were censored at first diagnosis of CRC, diagnosis of volvulus, date of resection or anastomosis, death, date of complete follow-up from national sources or at 15 years of follow-up.

Cancer incidence rates per 100,000 person-years were calculated. Cumulative cancer incidence through 15 years was computed and illustrated using Kaplan-Meier survival curves and compared between exposure subgroups using the log-rank test. Joint Cox proportional hazard models with follow-up time as the underlying time metric were used to estimate hazards ratios (HRs) and 95% confidence intervals (Cls) for the association between each adenoma characteristic and proximal colon cancer or distal CRC incidence, which were treated as competing risks [26]. Wald tests were used to examine heterogeneity in the associations of adenoma characteristics with each outcome. Multivariable models were constructed, adjusting for potential confounders which included age, sex, year of examination, bowel preparation quality, presence of hyperplastic polyps, length of the baseline visit and the number of surveillance visits (treated as a time-varying variable). Models were also constructed to examine the effect of additionally mutually adjusting for all adenoma characteristics to assess which were independently associated with the outcome. Adjustment for the examination centre did not materially make a difference to the associations observed and therefore it was not included in the final models.

All variables were included as main-effect terms in the final models. Proportionality of the association between each adenoma characteristic and cancer incidence over time was assessed by a statistical test for an interaction of Schoenfeld residuals with time. There was no evidence that associations differed over time.

Two sensitivity analyses were performed. In one, patients diagnosed with both proximal colon cancer and distal CRC were excluded from analyses. In the other, due to a lack of consensus on definitions, colorectal subsites were reclassified with the proximal colon subsite redefined as the caecum to the hepatic flexure [ICD-O-3 codes C18.0–C18.3] and the distal colorectum redefined as the transverse colon to the anus [ICD-O-3 codes C18.4–C18.7; C19; C20; C21]).

In secondary analyses, associations between 'high-risk' findings and proximal colon cancer were examined. High-risk findings were defined according to the most recent 2020 UK surveillance guidelines as: ≥ 2 premalignant polyps [serrated polyps or adenomas] including ≥ 1 advanced colorectal polyp [a ≥ 10 mm serrated polyp, a serrated polyp




Fig. 1 Patient flow diagram. This flow chart shows the total number of patients identified who underwent a lower gastrointestinal endoscopy along with the relevant exclusions made to arrive at the number of patients included for analysis and the number of accrued colorectal cancer cases. ^a conditions reported are not mutually exclusive. ^b a colonoscopy is considered complete if the colonoscope has reached the caecum. ^c proximal colon cancer incidence is defined as cancer located between the caecum and splenic flexure, International Classification of Diseases for Oncology, third edition (ICD-O-3) codes C18.0–C18.5. ^d distal colorectal cancer is defined as cancer located between the descending colon and the anus, ICD-O-3 codes C18.6–C18.7; C19; C20; C21.

with dysplasia, a \geq 10 mm adenoma or an adenoma with high-grade dysplasia] or \geq 5 premalignant polyps or a \geq 20 mm non-pedunculated colorectal polyp [14]. These models were examined both with and without consideration of any additional adenoma characteristics found to be independently associated with proximal colon cancer in the main analyses.

All analyses were conducted using Stata $^{\circ}$ version 13.1 [27]. All statistical tests were two-sided and *p*-values < 0.05 were considered statistically significant.

RESULTS

Patient and examination characteristics

A lower gastrointestinal endoscopy was performed in 253,798 patients. Among these, 235,321 patients were excluded, comprising 174,980 with no adenomas detected, 2859 patients with no baseline colonoscopy, 45,843 patients with CRC or other colonic conditions, 12 with carcinoma in situ diagnosed more than 3 years prior to baseline, 94 with missing examination dates, 6328 without a complete baseline colonoscopy, 3226 with a baseline examination before 2001, 15 with a baseline colonoscopy after 2010 and 1964 with missing data for at least one adenoma characteristic. Of eligible patients, 46 (0.2%) were excluded as a result of being lost to follow-up. A total of 18,431 patients remained for inclusion in analyses (Fig. 1).

Patients were followed up for a median of 9.8 years (IQR 7.4–11.9 years), during which 152 patients were diagnosed with proximal colon cancer and 105 with distal CRC; specific locations are given in Appendix Table 1.

British Journal of Cancer

The distribution of patient and examination characteristics in the study population and by baseline adenoma characteristics are presented in Table 1. The study population was 58.4% male, and the majority were between 55 and 74 years of age at baseline (60.0%), had their colonoscopy performed after 2005 (56.7%), had a baseline visit that spanned only 1 day (66.2%) and only 5.8% had poor bowel preparation quality (Table 1). During follow-up, over half (52.2%) of the patients had ≥ 1 surveillance visit (Table 1); among these patients, the time interval between visits was most commonly between >1-3 years or >3-5 years (Appendix Table 2). Patients with ≥ 3 adenomas, adenomas which were large (≥ 10 mm), tubulovillous or villous, with high-grade dysplasia or located in the proximal colon were more likely to be older or have attended their first surveillance visit within 3 years post-baseline colonoscopy compared to patients with < 3 adenomas, adenomas which were only small, tubular, with low-grade dysplasia or located distally, respectively (Table 1, Appendix Table 3). Patients with ≥ 3 adenomas adenomas which were large (≥ 10 mm). tubulovillous or villous, or with high-grade dysplasia were also more likely to have had a baseline visit performed over more than 1 day and more likely to have had follow-up surveillance compared to patients with <3 adenomas, adenomas which were only small, tubular or with low-grade dysplasia, respectively (Table 1).

Compared to patients without a CRC diagnosis, patients with proximal colon cancer were more likely to be women, older, to

Table 1. Baseline pat	ient and e	examinat	tion characterist	cics and numbe	Baseline patient and examination characteristics and number of follow-up visits by baseline adenoma characteristics.	isits by baselir	ie adenoma cha	aracteristics.				
			Adenoma characteristics	racteristics								
			Number		Size		Histology		Dysplasia		Location	
	All patients (N, %)	ents	ŝ	53	<10 mm	≥10 mm	Tubular	Tubulovillous/ villous	Low grade	High grade	Distal only	Any proximal
Baseline characteristics												
All patients, N (%)	18,431	100.0	15,751 (85.5)	2680 (14.5)	10,188 (55.3)	8243 (44.7)	11,562 (62.7)	6869 (37.3)	16,504 (89.5)	1927 (10.5)	10,887 (59.1)	7544 (40.9)
Sex, %												
Men	10,755	58.4	56.3	70.6	57.5	59.4	58.3	58.4	58.2	59.3	56.5	61.0
Women	7676	41.6	43.7	29.4	42.5	40.6	41.7	41.6	41.8	40.7	43.5	39.0
Age group (years), %												
<55	3586	19.5	21.1	9.8	22.5	15.7	21.7	15.7	20.3	12.2	22.7	14.8
55-64	5036	27.3	27.1	28.4	27.8	26.8	28.0	26.1	27.6	24.9	27.5	27.1
65-74	6020	32.7	31.5	39.4	30.6	35.2	31.4	34.8	32.2	36.9	31.1	35.0
≥75	3789	20.6	20.2	22.5	19.1	22.3	18.9	23.4	19.9	25.9	18.8	23.1
Year of examination, %	%											
2001-2005	7975	43.3	43.9	39.7	43.8	42.6	43.3	43.2	42.9	46.5	45.1	40.6
2006-2010	10,456	56.7	56.1	60.3	56.2	57.4	56.7	56.8	57.1	53.5	54.9	59.4
Bowel preparation quality, %	ality, %											
Excellent or good	6490	35.2	34.6	39.0	34.0	36.7	32.7	39.4	34.9	37.5	35.1	35.3
Satisfactory	3749	20.3	20.7	18.1	20.5	20.1	19.7	21.5	20.4	20.2	21.3	18.9
Poor	1071	5.8	5.8	5.8	6.3	5.2	5.9	5.7	6.0	4.5	5.8	5.8
Unknown	7121	38.6	38.9	37.1	39.1	38.1	41.7	33.4	38.7	37.8	37.7	40.0
Length of baseline visit, %	sit, %											
1 day	12,199	66.2	68.9	50.1	77.8	51.9	74.9	51.5	69.8	35.7	61.9	72.4
2 days–3 months	2800	15.2	14.7	18.4	10.1	21.4	12.1	20.4	14.4	21.8	18.4	10.6
>3-6 months	1804	9.8	8.9	15.1	6.9	13.4	7.3	14.0	8.7	19.5	10.8	8.4
≥6 months	1628	8.8	7.5	16.4	5.2	13.3	5.8	14.0	7.2	23.0	9.0	8.7
Hyperplastic polyps, %	%											
None/Only adenomas	14,623	79.3	80.8	70.9	78.9	79.9	78.8	80.2	79.3	80.0	80.4	77.8
	3808	20.7	19.2	29.1	21.1	20.1	21.2	19.8	20.7	20.0	19.6	22.2
Follow-up characteristics	S											
Surveillance visits, %												
None	8818	47.8	49.8	36.2	53.9	40.3	51.4	41.8	49.1	37.1	47.8	47.9
-	5122	27.8	27.9	26.9	27.6	28.1	27.3	28.7	27.7	28.5	28.4	26.9
2	2980	16.2	15.3	21.2	12.5	20.7	14.3	19.2	15.6	20.8	16.4	15.8
≥3	1511	8.2	6.9	15.7	6.0	10.9	7.0	10.2	7.6	13.6	7.4	9.4

4

R. Harewood et al.

Baseline characteristics	Patients	Cases	Person time (years)	Incidence rate per 100,000 person-years (95% Cl)	Cumulative incidence (%) ^a	<i>p</i> -value ^b
Proximal colon cancer incide	nce					
All patients	18,431	152	169,143	90 (77–105)	1.4 (1.2–1.7)	
Number of adenomas						
<3	15,751	107	146,385	73 (60–88)	1.2 (0.9–1.4)	
≥3	2680	45	22,758	198 (148–265)	3.0 (2.1–4.2)	<0.001
Adenoma size (mm)						
<10	10,188	76	95,691	79 (63–99)	1.2 (0.9–1.6)	
≥10	8243	76	73,452	103 (83–130)	1.6 (1.3–2.1)	0.084
Adenoma histology						
Tubular	11,562	77	107,615	72 (57–89)	1.1 (0.8–1.4)	
Tubulovillous or villous	6869	75	61,528	122 (97–153)	2.0 (1.5–2.5)	0.001
Adenoma dysplasia						
Low grade	16,504	133	152,448	87 (74–103)	1.4 (1.1–1.7)	
High grade	1927	19	16,695	114 (73–178)	1.6 (1.0–2.6)	0.254
Adenoma location						
Distal only	10,887	67	102,967	65 (51–83)	1.0 (0.8–1.3)	
Any proximal	7544	85	66,176	128 (104–159)	2.0 (1.6–2.6)	<0.001
Distal colorectal cancer incide	ence					
All patients	18,431	105	169,143	62 (51–75)	1.0 (0.8–1.3)	
Number of adenomas						
<3	15,751	85	146,385	58 (47–72)	0.9 (0.7–1.1)	
≥3	2680	20	22,758	88 (57–136)	1.9 (0.9–4.0)	0.084
Adenoma size (mm)						
<10	10,188	52	95,691	54 (41–71)	0.8 (0.6–1.2)	
≥10	8243	53	73,452	72 (55–94)	1.2 (0.8–1.8)	0.137
Adenoma histology						
Tubular	11,562	58	107,615	54 (42–70)	0.7 (0.5–1.0)	
Tubulovillous or villous	6869	47	61,528	76 (57–102)	1.5 (1.0–2.3)	0.070
Adenoma dysplasia						
Low grade	16,504	82	152,448	54 (43–67)	0.8 (0.6–1.0)	
High grade	1927	23	16,695	138 (92–207)	2.9 (1.6–5.2)	<0.001
Adenoma location						
Distal only	10,887	63	102,967	61 (48–78)	1.0 (0.7–1.3)	
Any proximal	7544	42	66,176	63 (47–86)	1.0 (0.6–1.7)	0.821
^a At 15 years of follow-up.						

Table 2.	Colorectal cancer	r incidence by	[,] baseline	adenoma	characteristics.
----------	-------------------	----------------	-----------------------	---------	------------------

^aAt 15 years of follow-up.

^bp-values calculated with the log-rank test comparing cumulative incidence for adenoma characteristic subgroups.

have had their baseline colonoscopy prior to 2005, have a baseline visit spanning more than 1 day, to have hyperplastic polyps detected, ≥ 3 adenomas, a large (≥ 10 mm) adenoma, adenomas with tubulovillous or villous histology or proximal adenomas. They were also more likely to have fewer follow-up surveillance visits (Appendix Table 4). Compared to those with proximal colon cancer, patients with distal CRC were, however, less likely to be women, and their baseline colonoscopy was more likely to have poor bowel preparation or adenomas with high-grade dysplasia detected and less likely to have hyperplastic polyps, ≥ 3 adenomas or any proximal adenoma detected (Appendix Table 4).

Baseline adenoma characteristics and proximal colon cancer or distal CRC risk

The incidence rate of proximal colon cancer was 90 (95% Cl: 77–105) per 100,000 person-years (Table 2) and overall cumulative incidence at 15 years was 1.4% (95% Cl: 1.2–1.7%) (Table 2, Fig. 2).

Cumulative incidence was significantly higher for patients with ≥ 3 adenomas compared to <3 (p < 0.001), adenomas with tubulovillous or villous histology compared to only tubular (p = 0.001) and those with any proximal compared to only distal adenomas (p < 0.001) (Table 2, Fig. 2).

The incidence rate of distal CRC was 62 (95% CI: 51–75) per 100,000 person-years (Table 2) and overall cumulative incidence at 15 years was 1.0% (95% CI: 0.8–1.3%) (Table 2, Fig. 3). Cumulative incidence was significantly higher for patients with adenomas with high-grade compared to low-grade dysplasia (p < 0.001), but no differences were observed by subgroup of adenoma number, size, histology nor location (Table 2, Fig. 3).

In crude analyses, \geq 3 adenomas compared to <3 adenomas, tubulovillous or villous histology compared to tubular, and proximal adenomas compared to only distal adenomas were associated with a higher risk of proximal colon cancer; these associations remained after adjustment for potential confounders




Fig. 2 Cumulative incidence curves (%) for proximal colon cancer within 15 years of follow-up. The graphs show Kaplan-Meier survival curves for proximal colon cancer incidence: a overall; b by the number of adenomas; c by adenoma size (mm); d by adenoma histology; e by adenoma dysplasia; f by adenoma location. A different scale has been used in the graph for adenoma number and is highlighted by an asterisk. The p-values presented are for the log-rank test to compare curves for subgroups of each adenoma characteristic. The 95% Cls for each curve are shown as shaded bands.

(Table 3). When also mutually adjusting for adenoma characteristics, \geq 3 adenomas compared to < 3 (adjusted HR [aHR] 2.10, 95% CI: 1.42–3.09, p < 0.001) and adenomas with tubulovillous or villous histology compared to tubular (aHR 1.61, 95% CI: 1.10–2.35, p = 0.015) were independently associated with an increased risk of incident proximal colon cancer (Table 3). Despite not being associated with distal CRC in crude or adjusted models, there was no evidence of heterogeneity in the effect of adenoma number (p-heterogeneity = 0.205) or histology (p-heterogeneity = 0.260) on CRC by subsite.

Having any proximal adenoma compared to only distal adenomas was positively and independently associated with proximal colon cancer (aHR 1.70, 95% CI: 1.20–2.42, p = 0.003) but was not associated with distal CRC with borderline evidence of a difference in the effect by subsite (p-heterogeneity = 0.055). Conversely, having had adenomas displaying high-grade dysplasia




Fig. 3 Cumulative incidence curves (%) for distal colorectal cancer within 15 years of follow-up. The graphs show Kaplan-Meier survival curves for distal colorectal cancer incidence: a overall; b by the number of adenomas; c by adenoma size (mm); d by adenoma histology; e by adenoma dysplasia; f by adenoma location. A different scale has been used in the graph for adenoma number and adenoma dysplasia and is highlighted by an asterisk. The p-values presented are for the log-rank test to compare curves for subgroups of each adenoma characteristic. The 95% Cls for each curve are shown as shaded bands.

at baseline, compared to those with only adenomas displaying low-grade dysplasia, was independently associated with an increased risk of distal CRC incidence (aHR 2.42, 95% CI: 1.44–4.04, p = 0.001) but was not associated with proximal colon cancer risk (p-heterogeneity = 0.023) (Table 3).

The median time to diagnosis among patients with proximal adenomas and at least one other adenoma characteristic which was independently associated with proximal colon cancer was 5.2

(IQR 3.0–8.1) compared to 6.9 (IQR 3.9–10.2) years for those with proximal adenomas as the only characteristic detected (Appendix table 5). For patients with ≥3 adenomas, the median time to diagnosis was 5.4 (IQR 3.0–9.3) (including patients with ≥1 other adenoma characteristic) compared to 6.2 (IQR 4.6–7.9) years for patients with ≥3 adenomas alone, although there were only two cases in this group. For patients with tubulovillous or villous adenomas this was 4.8 (IQR 2.6–9.4) (including patients with ≥1

5 Fatorial Cardinal fragmential Portion	5 Paterial Gase of the control of the c												•
othera	ordered 13/531 123 - - - - 13/531 123 - - - - - 13/531 10 100 100 100 100 - - 13/531 10 100 003 010 013 010 010 - - 13/531 70 100 010 010 010 010 010 010 - <	Baseline characteristics	Patients	Cases	Crude HR (95% CI)	p-value"	<i>p</i> -value het ^b	Adjusted HR (95% Cl) ^c	p-value"	<i>p</i> -value het ^b	Adjusted HR (95% Cl) ^d	<i>p</i> -value	<i>p</i> -value het ^b
431 123 - - - - - - - 573 107 100 100 100 100 101 100 2101(14.3.10) 4001 108 76 106 106 100 0001 0002 110(14.3.10) 4001 108 76 106 106 106 100 0002 100 0003 0003 108 75 106(11.2.30) 0003 106(12.0.204) 0003 106(110.2.30) 0003 108 75 107(12.1.240) 0003 108 003 106(110.2.30) 003 108 10 108 100 001 100 003 101(10.2.30) 003 108 10 108 108 108 108 108 108 108 10 108 103 108 103 103 103 108 10 10 100 103 103 1	18,31 12 - 100 100 <th1< td=""><td>Proximal colon cancer incider</td><td>nce</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th1<>	Proximal colon cancer incider	nce										
	15751 107 100 </td <td>All patients</td> <td>18,431</td> <td>152</td> <td>I</td> <td></td> <td></td> <td>I</td> <td></td> <td></td> <td>1</td> <td></td> <td></td>	All patients	18,431	152	I			I			1		
15751 107 100<	15751 107 100 </td <td>Number of adenomas</td> <td></td>	Number of adenomas											
	280 3 245 (130-36) 4001 0025 210 (142-30) 4001 0050 210 (142-30) 4001 1018 7 100 126 (03-1-12) 0161 0386 135 (03-1-12) 010 068 100 068 050 100 (068-11) 068 068 135 (03-1-12) 068 100 069 100 (068-11) 068 069 100 069 100 068 100 068 100 068 100 068 100 068 100 068 100 068 100 068 100 068 100 068 100 068 100 068 100 068 100 069 101 100	Ŷ	15,751	107	1.00			1.00			1.00		
International (1) Internation (1) Internation (1) <	1 10185 56 100	S.	2680	45	2.56 (1.80-3.63)	<0.001	0.052	2.77 (1.94–3.94)	<0.001	0.050	2.10 (1.42–3.09)	<0.001	0.205
	10.188 76 10.0 <th< td=""><td>Adenoma size (mm)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	Adenoma size (mm)											
823 75 126 (03) (13) 0101 0366 157 (04) (06) (15) 046 057 032 104 (06) (15) 066 1152 7 100 002 043 166 (12) (12) (12) 010 100 010 1152 7 100 002 043 166 (12) (12) (12) (12) 010 100 101 101 013 013 1650 13 100 034 031 001 120 (12) (12) (12) (12) (12) (12) (12) (12)	22.3 76 1.26 (0.91-1.7) 0.161 0.966 1.57 (0.61-5.7) 0.666-1.57 0.666 105 67 106 106 0.012 1.29 0.602 0.61 1.01 0.63	<10	10,188	76	1.00			1.00			1.00		
II 50 T 100 <td>11562 7 100 100 100 100 100 100 100 100 100 101<td>≥10</td><td>8243</td><td>76</td><td>1.26 (0.91–1.73)</td><td>0.161</td><td>0.986</td><td>1.35 (0.97–1.86)</td><td>0.072</td><td>0.992</td><td>1.04 (0.68–1.57)</td><td>0.862</td><td>0.991</td></td>	11562 7 100 100 100 100 100 100 100 100 100 101 <td>≥10</td> <td>8243</td> <td>76</td> <td>1.26 (0.91–1.73)</td> <td>0.161</td> <td>0.986</td> <td>1.35 (0.97–1.86)</td> <td>0.072</td> <td>0.992</td> <td>1.04 (0.68–1.57)</td> <td>0.862</td> <td>0.991</td>	≥10	8243	76	1.26 (0.91–1.73)	0.161	0.986	1.35 (0.97–1.86)	0.072	0.992	1.04 (0.68–1.57)	0.862	0.991
	11,52 7 100 <td>Adenoma histology</td> <td></td>	Adenoma histology											
vilous 666 75 167(1,12,-230) 0002 0450 161(1,0-235) 010 16504 13 100 032 100 033 100 033 1937 13 100 034 0301 129 (080-208) 033 100 013 1937 67 100 0312 0001 0101 129 (080-208) 033 100 033 1937 68 190 (144-274) 0001 0101 202 (146-281) 0301 100 (120-242) 033 atriotime 1 1 1 1 1 1 1 1 1 0<	villous 666 75 16/(1,12,12,30) 0.002 0.450 16/(1,10,-25) 0.015 15,504 13 100 0.342 0.031 1.00 0.333 15,504 13 1.00 0.342 0.051 1.26 (0.76-2.04) 0.342 0.051 1.00 0.033 1.00 0.033 1.00 0.033 1.00 0.033 1.00 0.033 1.00 0.033 1.00 0.033 1.00 0.033 <	Tubular	11,562	77	1.00			1.00			1.00		
16504 13 100 </td <td>1504 13 100 130 100 130 100 130 100 130 100 130 100 130 100 130 100 130 100 130 100 130 100<td>Tubulovillous or villous</td><td>6869</td><td>75</td><td>1.67 (1.21–2.30)</td><td>0.002</td><td>0.453</td><td>1.66 (1.20–2.28)</td><td>0.002</td><td>0.450</td><td>1.61 (1.10–2.35)</td><td>0.015</td><td>0.260</td></td>	1504 13 100 130 100 130 100 130 100 130 100 130 100 130 100 130 100 130 100 130 100 130 100 <td>Tubulovillous or villous</td> <td>6869</td> <td>75</td> <td>1.67 (1.21–2.30)</td> <td>0.002</td> <td>0.453</td> <td>1.66 (1.20–2.28)</td> <td>0.002</td> <td>0.450</td> <td>1.61 (1.10–2.35)</td> <td>0.015</td> <td>0.260</td>	Tubulovillous or villous	6869	75	1.67 (1.21–2.30)	0.002	0.453	1.66 (1.20–2.28)	0.002	0.450	1.61 (1.10–2.35)	0.015	0.260
	16504 133 100 </td <td>Adenoma dysplasia</td> <td></td>	Adenoma dysplasia											
1927 19 12.6 (0.78-2.04) 0.34 0.051 12.9 (0.80-1.05) 0.55 16.6 (0.4-1.73) 0.833 10387 67 100 100 0.01 0.012 1.00 1.00 0.033 7544 57 100 0.012 0.012 0.012 0.013 1.00 0.013 1.00 0.013 0.033 st indefence 105 -	1927 19 126 (0.78-2.04) 0.342 0.051 129 (0.80-2.06) 0.32 105 (0.64-1.73) 0.833 10.887 67 100 100 0.012 120 (0.04-2.04) 0.031 100 100 2544 85 199 (144-274) <0.001	Low grade	16,504	133	1.00			1.00			1.00		
10887 67 100 <td>10387 67 100 101 1.00 1.</td> <td>High grade</td> <td>1927</td> <td>19</td> <td>1.26 (0.78–2.04)</td> <td>0.342</td> <td>0.051</td> <td>1.29 (0.80–2.08)</td> <td>0.291</td> <td>0.052</td> <td>1.05 (0.64–1.73)</td> <td>0.833</td> <td>0.023</td>	10387 67 100 101 1.00 1.	High grade	1927	19	1.26 (0.78–2.04)	0.342	0.051	1.29 (0.80–2.08)	0.291	0.052	1.05 (0.64–1.73)	0.833	0.023
10887 67 100 <td>10887 67 100<td>Adenoma location</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td>	10887 67 100 <td>Adenoma location</td> <td></td>	Adenoma location											
7544 85 199 (144-274) <001 0.012 2.02 (146-281) <001 1.70 (120-242) 0.003 rinddence 105 - - - - - - 0.01 1.70 (120-242) 0.003 as 15751 85 -	754 85 199 (144-2/4) 6.001 0.012 2.02 (146-2.81) 6.001 0.011 1.70 (120-2.42) 0.003 reincidence 1	Distal only	10,887	67	1.00			1.00			1.00		
rer incidence 18,431 105 - <	er incidence 3 - - as 100 100 100 as 100 100 100 as 100 100 as 100 100 2680 20 141 (0.86-2.30) 0.172 139 (0.83-2.32) 100 as 10188 52 1.00 1.00 1.00 1.00 1.00 astat 1.1562 58 1.00 0.129 0.109 0.129 1.03 (0.62-1.73) at 11562 58 1.00 0.00 1.00 1.00 1.00 1.00 at 11562 58 1.00 0.013 0.129 0.113 0.129 1.03 (0.62-1.73) at 11562 58 1.00 0.020 0.100 0.104 1.00 0.00 at 11562 58 1.03 (0.92-2.02) 0.113 0.103 0.101 1.00 1.00	Any proximal	7544	85	1.99 (1.44–2.74)	<0.001	0.012	2.02 (1.46–2.81)	<0.001	0.011	1.70 (1.20–2.42)	0.003	0.055
18,31 105 - - - - - - as 15/51 85 100 100 130 (032-234) 130 (032-232) 2680 20 141 (086-230) 0172 151 (022-249) 0.104 130 (033-232) 1 2680 20 141 (086-136) 0.235 135 (092-199) 0.104 130 (052-173) 1 10188 52 100 135 (092-199) 0.109 103 (062-173) 1 1018 53 12.6 (086-188) 0.235 135 (092-199) 0.109 103 (062-173) 1 1018 53 12.6 (086-188) 0.235 135 (092-199) 0.109 103 (062-173) 1 1056 689 47 138 (094-203) 0.105 137 (092-190) 103 (062-173) 1 16564 82 100 137 (092-203) 0.118 100 (066-132) 1 16564 82 100 100 100 100 1 1557 138	18,431 105 - - - - - - as 15/751 85 100 100 100 100 100 2680 20 141(0.86-230) 0.172 151(0.92-249) 0.104 130(0.83-232) 1 10188 52 100 100 100 100 1 10188 52 100 0.172 135(0.92-149) 0.104 130(0.82-173) 1 10188 52 126(0.86-1.85) 0.235 135(0.92-199) 0.129 103(0.62-173) 1 10188 53 126(0.86-1.85) 0.235 137(0.92-2.02) 0.139 103(0.62-173) 1 1562 58 100 137(0.92-2.02) 0.118 103(0.62-173) 1 1556 689 47 138(0.94-2.03) 0.105 103(0.62-173) 1 1556 137(0.92-2.02) 0.118 137(0.92-2.02) 0.118 1.12(0.66-1.13) 1 1557 28 1	Distal colorectal cancer incide	ence										
15/1 15/1 100 </td <td>as 15/51 85 1.00 1.10 1.30 (0.32-230) 1.00 1.00 1.30 (0.32-232) 2680 20 1.41 (0.86-230) 0.172 1.51 (0.92-249) 0.104 1.30 (0.83-232) 1.01 1.018 52 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.0</td> <td>All patients</td> <td>18,431</td> <td>105</td> <td>I</td> <td></td> <td></td> <td>ı</td> <td></td> <td></td> <td>I</td> <td></td> <td></td>	as 15/51 85 1.00 1.10 1.30 (0.32-230) 1.00 1.00 1.30 (0.32-232) 2680 20 1.41 (0.86-230) 0.172 1.51 (0.92-249) 0.104 1.30 (0.83-232) 1.01 1.018 52 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.0	All patients	18,431	105	I			ı			I		
15,751 85 100 1.00 2680 20 1.41 (0.86-2.30) 0.172 1.51 (0.92-2.49) 0.104 1.39 (0.83-2.32) 10,188 52 1.00 1.00 1.00 1.00 1.00 8243 53 1.26 (0.86-1.85) 0.235 1.35 (0.92-1.99) 0.129 1.00 11,562 58 1.00 1.36 (0.92-2.02) 0.129 1.00 1.00 villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.00 villous 16,504 82 1.00 1.00 1.37 (0.92-2.02) 0.118 1.03 (0.62-1.73) villous 6869 47 1.38 (0.94-2.03) 0.105 1.00 1.00 1.00 villous 16,504 82 1.00 1.37 (0.92-2.02) 0.118 1.120 (0.68-1.84) 1.00 villous 10,504 2.34 (0.47-4.04) 2.34 (0.44-4.04) 2.34 (0.44-4.04) 1.00 10087 63 1.00 1.00	15,751 85 1.00 1.00 1.00 2680 20 1.41 (0.86-2.30) 0.172 1.51 (0.92-2.49) 0.104 1.39 (0.83-2.32) 10,188 52 1.00 1.30 (0.92-2.49) 0.104 1.39 (0.83-2.32) 8243 53 1.26 (0.86-1.85) 0.235 1.35 (0.92-1.99) 0.129 1.00 8243 53 1.26 (0.86-1.85) 0.235 1.37 (0.92-2.02) 0.139 1.00 villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.00 villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.00 villous 16504 82 1.00 1.37 (0.92-2.02) 0.118 1.00 villous 16504 82 0.001 2.36 (1.55-4.03) 0.001 2.42 (1.44-4.04) 1927 23 2.45 (1.54-3.30) 0.001 2.50 (1.55-4.03) 0.001 2.42 (1.44-4.04) 1087 63 0.04 0.0001 <td>Number of adenomas</td> <td></td>	Number of adenomas											
2680 20 141 (0.86-2.30) 0.172 151 (0.92-2.49) 0.104 1.39 (0.83-2.32) 10188 52 1.00 1.00 1.00 1.00 1.00 8243 53 1.26 (0.86-1.85) 0.235 1.35 (0.92-1.99) 0.129 1.03 (0.62-1.73) 8243 53 1.26 (0.86-1.85) 0.235 1.35 (0.92-1.99) 0.129 1.03 (0.62-1.73) villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.03 (0.62-1.73) villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.03 (0.62-1.73) villous 6869 47 1.38 (0.94-2.03) 0.105 1.03 (0.62-1.73) 1.03 (0.62-1.84) villous 6869 47 1.38 (0.94-2.03) 0.105 1.00 1.00 villous 16504 82 1.00 2.30 (1.55-4.03) 2.40 (1.44-4.04) 1927 2.3 1.04 2.30 (1.55-4.03) 2.40 (1.44-4.04) 10284 63	2680 20 141 (0.86-2.30) 0.172 1.51 (0.92-2.49) 0.104 1.39 (0.83-2.32) 10/188 52 1.00 1.00 1.00 1.00 1.00 8243 53 1.26 (0.86-1.85) 0.235 1.35 (0.92-1.99) 0.129 1.00 8243 53 1.26 (0.86-1.85) 0.235 1.35 (0.92-1.99) 0.129 1.00 vilous 869 47 1.38 (0.94-2.03) 0.105 1.00 1.03 1.05 vilous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.03 vilous 6869 47 1.38 (0.94-2.03) 0.0105 1.37 (0.92-2.02) 0.118 vilous 16,504 82 1.00 1.37 (0.92-2.02) 0.118 1.03 (0.61-1.64) vilous 6869 47 1.38 (0.94-2.03) 0.0105 2.45 (1.44-4.04) vilous 1927 23 2.45 (1.54-3.90) 0.001 2.60 (1.55-4.03) 2.02 (1.44-4.04) 7544 42	ŝ	15,751	85	1.00			1.00			1.00		
10188 52 1.00 1.10 1.00 1.10 <th1< td=""><td>10188 52 100 100 8243 53 126 (086-1.85) 0.235 135 (0.92-1.99) 0.129 1.03 (062-1.73) 8243 53 1.26 (086-1.85) 0.235 1.35 (0.92-1.99) 0.129 1.03 (062-1.73) villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.12 (068-1.84) 16504 82 1.00 1.37 (0.92-2.02) 0.118 1.12 (068-1.84) 16504 82 1.00 1.37 (0.92-2.02) 0.118 1.12 (068-1.84) 16504 82 1.00 1.37 (0.92-2.02) 0.118 1.12 (0.68-1.84) 1927 23 2.45 (1.54-3.90) <0.001</td> 2.50 (1.55-4.03) <0.001</th1<>	10188 52 100 100 8243 53 126 (086-1.85) 0.235 135 (0.92-1.99) 0.129 1.03 (062-1.73) 8243 53 1.26 (086-1.85) 0.235 1.35 (0.92-1.99) 0.129 1.03 (062-1.73) villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.12 (068-1.84) 16504 82 1.00 1.37 (0.92-2.02) 0.118 1.12 (068-1.84) 16504 82 1.00 1.37 (0.92-2.02) 0.118 1.12 (068-1.84) 16504 82 1.00 1.37 (0.92-2.02) 0.118 1.12 (0.68-1.84) 1927 23 2.45 (1.54-3.90) <0.001	≥3	2680	20	1.41 (0.86–2.30)	0.172		1.51 (0.92–2.49)	0.104		1.39 (0.83–2.32)	0.206	
	10188 52 1.00 1.10 0.018 1.10 0.001 1.10 0.001 1.10 0.001 1.10 0.001 1.00 2.40 1.40 1.00 2.40 2.40 2.40 2.40 2.40 2.40 2.40 1.40 1.00 2.40 1.40 1.00 2.40 1.40 1.00 2.40 1.40 1.00 2.40 1.40 2.40 1.40 2.40 1.40 2.40 1.40 2.40 1.40 2.40 1.40 2.40 2.40 2.40 2.40	Adenoma size (mm)											
8243 53 126 (0.86-1.85) 0.235 1.35 (0.92-1.99) 0.129 1.03 (0.62-1.73) villous 58 1.00 1.00 1.00 1.00 villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.12 (0.68-1.84) villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.12 (0.68-1.84) villous 6869 82 1.00 1.37 (0.92-2.02) 0.118 1.12 (0.68-1.84) 16,504 82 1.00 2.50 (1.55-4.03) 0.118 1.12 (0.68-1.84) 1927 23 2.45 (1.54-3.90) <0.001	8243 53 1.26 (0.86-1.85) 0.235 1.35 (0.92-1.90) 0.129 1.03 (0.62-1.73) 11,562 58 1.00 1.00 1.00 1.00 1.00 villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.12 (0.68-1.84) villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.12 (0.68-1.84) villous 6869 82 1.00 1.37 (0.92-2.02) 0.118 1.12 (0.68-1.84) 16,504 82 1.00 2.45 (1.54-3.90) <0.001	<10	10,188	52	1.00			1.00			1.00		
11,562 58 1.00 1.00 1.00 1.20 <th< td=""><td>11,562 58 1.00 1.00 1.00 1.20 <th< td=""><td>≥10</td><td>8243</td><td>53</td><td>1.26 (0.86–1.85)</td><td>0.235</td><td></td><td>1.35 (0.92–1.99)</td><td>0.129</td><td></td><td>1.03 (0.62–1.73)</td><td>0.900</td><td></td></th<></td></th<>	11,562 58 1.00 1.00 1.00 1.20 <th< td=""><td>≥10</td><td>8243</td><td>53</td><td>1.26 (0.86–1.85)</td><td>0.235</td><td></td><td>1.35 (0.92–1.99)</td><td>0.129</td><td></td><td>1.03 (0.62–1.73)</td><td>0.900</td><td></td></th<>	≥10	8243	53	1.26 (0.86–1.85)	0.235		1.35 (0.92–1.99)	0.129		1.03 (0.62–1.73)	0.900	
11,562 58 1.00 1.00 villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.12 (0.68-1.84) 16,504 82 1.00 1.37 (0.92-2.02) 0.118 1.12 (0.68-1.84) 1927 23 1.36 (0.94-2.03) 0.105 1.00 2.43 (1.54-3.90) 1927 23 2.45 (1.54-3.90) <0.001	11,562 58 1.00 1.00 villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.12 (0.68-1.84) 16,504 82 1.00 1.37 (0.92-2.02) 0.118 1.12 (0.68-1.84) 16,504 82 1.00 2.45 (1.54-3.90) 0.001 2.50 (1.55-4.03) 2.42 (1.44-4.04) 1927 23 2.45 (1.54-3.90) <0.001	Adenoma histology											
villous 6869 47 1.38 (0.94-2.03) 0.105 1.37 (0.92-2.02) 0.118 1.12 (0.68-1.84) 16,504 82 1.00 1.00 1.00 1.00 1927 23 2.45 (1.54-3.90) <0.001	villous 6869 47 1.38 (0.94–2.03) 0.105 1.37 (0.92–2.02) 0.118 1.12 (0.68–1.84) 16,504 82 1.00 1.00 1.00 1927 23 2.45 (1.54–3.90) <0.001 2.50 (1.55–4.03) <0.001 2.42 (1.44–4.04) 10,887 63 1.00 2.001 2.50 (1.55–4.03) <0.001 2.42 (1.44–4.04) 7544 42 1.04 (0.70–1.53) 0.851 1.05 (0.71–1.57) 0.805 1.00 (0.66–1.52) t with the Wald test.	Tubular	11,562	58	1.00			1.00			1.00		
16,504 82 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 2.42 (1.44-4.04) 2.44 (1.44-4.04)	16,504 82 1.00 1.00 1.00 1927 23 2.45 (1.54-3.90) <0.001	Tubulovillous or villous	6869	47	1.38 (0.94–2.03)	0.105		1.37 (0.92–2.02)	0.118		1.12 (0.68–1.84)	0.656	
16,504 82 1.00 1.00 1927 23 2.45 (1.54-3.90) <0.001	16,504 82 1.00 1.00 1.00 1927 23 2.45 (1.54-3.90) <0.001	Adenoma dysplasia											
1927 23 2.45 (1.54-3.90) <0.001 2.50 (1.55-4.03) <0.001 2.42 (1.44-4.04) 10,887 6.3 1.00 1.00 1.00 1.00 1.00 7544 4.2 1.04 (0.70-1.53) 0.851 1.05 (0.71-1.57) 0.805 1.00 (0.66-1.52)	1927 23 2.45 (1.54-3.90) <0.001	Low grade	16,504	82	1.00			1.00			1.00		
10,887 63 1.00 1.00 1.00 7544 42 1.04 (0.70-1.53) 0.851 1.05 (0.71-1.57) 0.805 1.00 (0.66-1.52)	10,887 63 1.00 1.00 7544 42 1.04 (0.70-1.53) 0.851 1.05 (0.71-1.57) 0.805 1.00 (0.66-1.52) d with the Wald test. 1.00 control of and	High grade	1927	23	2.45 (1.54–3.90)	<0.001		2.50 (1.55–4.03)	<0.001		2.42 (1.44–4.04)	0.001	
1.00 1.00 1.00 1.05 (0.71–1.57) 0.805 1.00 (0.66–1.52)	1.00 1.00 1.05 (0.71–1.57) 0.805 1.00 (0.66–1.52)	Adenoma location											
1.05 (0.71–1.57) 0.805 1.00 (0.66–1.52)	1.05 (0.71–1.57) 0.805 1.00 (0.66–1.52)	Distal only	10,887	63	1.00			1.00			1.00		
HR hazard ratio.	<i>HR</i> hazard ratio. ² p-values calculated with the Wald test.	Any proximal	7544	42	1.04 (0.70–1.53)	0.851		1.05 (0.71–1.57)	0.805		1.00 (0.66–1.52)	0.994	
	^a p-values calculated with the Wald test.	HR hazard ratio.											

⁻*p*-value for heterogeneity in the effect between proximal colon and distal colorectal cancer. ^CAdjusted for sex, age, presence of hyperplastic polyps, year of examination, bowel preparation quality, length of baseline visit and number of surveillance visits as a time-varying covariate. ^dMutually adjusted for each adenoma characteristic, sex, age, presence of hyperplastic polyps, year of examination, bowel preparation quality, length of baseline visit and number of surveillance visits as a time-varying covariate. varying covariate.

8

other adenoma characteristic) compared to 7.1 (IQR 3.9–9.7) years for patients with tubulovillous or villous adenomas alone (Appendix Table 5).

In sensitivity analyses, results were similar after excluding patients diagnosed with both proximal colon cancer and distal CRC (Appendix table 6). Additionally, reclassifying proximal colon and distal colorectal subsite definitions did not materially alter findings with the exception that adenoma number was now associated with distal CRC (Appendix Table 7). In both analyses, there was also stronger evidence of heterogeneity in the association between adenoma location and CRC by subsite.

In secondary multivariable analyses adjusted for potential confounders previously identified, the presence of high-risk findings, as defined by the 2020 UK surveillance guidelines, was positively associated with proximal colon cancer (aHR 1.51, 95% CI: 1.05–2.16). However, upon the inclusion of adenoma number, histology or location to the multivariable model, this association was no longer statistically significant. Adenoma number (p < 0.001), histology (p = 0.032) and location (p = 0.001) were also all observed to be independently associated with proximal colon cancer in these models (data not shown).

DISCUSSION

To our knowledge, this is the largest cohort study to investigate the association between adenoma characteristics and the long-term incidence of proximal colon cancer compared to distal CRC among patients with adenomas at baseline colonoscopy. It revealed that, post-polypectomy, multiple (\geq 3) adenomas, tubulovillous or villous adenomas and proximal adenomas were independently associated with future proximal colon cancer but not with distal CRC, with borderline evidence of heterogeneity between CRC subsites for adenoma location. Adenoma dysplasia was associated with distal CRC whereas there was no association with proximal colon cancer and there was evidence of subsite heterogeneity.

The finding that proximal adenoma location was strongly associated with increased long-term proximal colon cancer incidence provides great insight into the natural history of proximal colon cancer. This lends weight to the idea that some proximal cancers arise via the adenoma-carcinoma pathway, and that the development of CRC via this pathway in the proximal colon may also be differential compared to that in the distal colorectum. This is supported by findings of a greater likelihood of proximally located metachronous adenomas after the detection of only proximal baseline adenomas compared to distal adenoma recurrence following the detection of only distal adenomas at baseline from a study based on data from three adenoma prevention trials and focused on adenoma recurrence as an outcome [3].

This current study also suggests that adenoma dysplasia may play a greater role in the development of distal CRC compared to proximal colon cancer but the small number of patients with baseline adenomas with high-grade dysplasia means that these results should be interpreted with caution. The higher risk of proximal colon cancer among patients with multiple (\geq 3) adenomas or tubulovillous or villous adenomas detected could also be reflective of a greater propensity for adenoma and cancer development [28] or of an increased likelihood for the development of more aggressive adenomas with faster progression rates to malignancy in these patients.

There is a greater likelihood for missed adenomas to occur in the proximal colon compared to the distal colorectum, resulting in post-polypectomy CRC [29, 30]. In order to mitigate some of the effects that poor colonoscopy quality might have on the observed associations, particularly in the proximal colon, our analysis was restricted to patients with a complete colonoscopy performed after the year 2000 when endoscopic quality criteria and methods to improve detection were introduced in the UK [31].

There are few studies investigating associations between adenoma characteristics at baseline colonoscopy and CRC, with even fewer conducting analysis of CRC by subsite [14-16]. To our knowledge, the only other study to investigate the association between polyp (including adenomas) characteristics (number, size, histology, dysplasia, location) at baseline colonoscopy and proximal colon cancer risk specifically was a case-control study conducted in Germany [2]. In line with our findings, this study found that the presence of multiple (\geq 3) polyps was associated with an over two-fold greater odds of proximal colon cancer. It also reported an increased risk of proximal colon cancer in patients with at least one proximal polyp at baseline compared to only distal polyps, but this was not statistically significant. Moreover, no other statistically significant associations were reported between any of the polyp characteristics under study and proximal colon cancer or distal CRC [2], although this may have been due to the smaller number of cancer cases in each subsite (proximal colon cancer [n = 97], distal CRC [n = 59]) in this previous analysis.

The present study benefited from the use of detailed data from 17 UK hospitals with wide geographic coverage, lending weight to the generalisability of the results. The use of routinely collected data from hospitals meant that the completeness and quality of endoscopy and pathology data were representative of standard hospital practice. The number of proximal colon cancer cases accrued was high due to the large cohort and long follow-up period, affording the opportunity to report on subsite-specific analyses, which is rare in many studies of this nature. The use of national cancer and vital statistics registries for outcome data on cancers, deaths and emigration resulted in a low proportion of patients who were lost to follow-up, minimising the likelihood of attrition bias. The availability of data on follow-up surveillance visits allowed for the differential surveillance contact between exposure groups to be accounted for, which is important because surveillance affects cancer outcomes.

Limitations of our study include the possibility of some measurement error or misclassification bias associated with data collected by hospitals. Data on endoscopist performance were not available for inclusion in analysis; however, as outcome data was unknown at the time of baseline colonoscopy, any bias is likely to have been non-differential leading to an attenuation of effect estimates. Data on the reason for the baseline colonoscopy referral were unavailable and therefore we were not able to disentangle any differences in the associations between adenoma characteristics in patients who were asymptomatic (i.e. attending screening) and those symptomatic. Moreover, some patients may have had a colonoscopy performed prior to our baseline, at which adenomas may have been removed thus reducing their risk as compared to patients for whom our baseline was their first colonoscopy; this may have affected our results if this was differential by exposure subgroups. Missing data for indicators of colonoscopy quality may also have biased results; however, the proportion of missingness was similar among patients with and without the main outcome. The exclusion of cancers thought to have arisen from incompletely resected adenomas at baseline could have resulted in an underestimation of the true effect of some adenoma characteristics on proximal colon cancer incidence in clinical practice.

Surveillance following baseline colonoscopy may have affected the risk of subsequent cancer in patients attending compared to those not attending. In this population of patients with baseline adenomas, among those who had follow-up surveillance colonoscopies, the majority attended within 5 years of their baseline visit, which was in line with recommendations at the time for patients with low- (5-year surveillance), intermediate- (3-year surveillance) or high-risk (1-year surveillance) adenomas at baseline [25]. Patients with adenomas which were numerous, large, tubulovillous or villous, or with high-grade dysplasia were more likely to have had a follow-up surveillance visit; this may have affected estimates in two divergent ways. These patients may have had other adenomas detected and removed during followup, reducing their risk of future cancer and resulting in an underestimation of the association between adenoma characteristics and CRC. Alternatively, they may have been more prone to surveillance bias, where having these characteristics may have increased their likelihood of having cancer detected due to greater contact with health services, resulting in an overestimation of the association between adenoma characteristics and CRC. Adjustment for the number of surveillance visits would have accounted for some of this in analyses but there is still the possibility of residual confounding due to differential surveillance regimes between subgroups of exposures.

The contribution of serrated polyps to CRC incidence via the serrated pathway has recently been recognised [32–35], with growing evidence of an increased likelihood of serrated polyps occurring post-colonoscopy, especially in the proximal colon [36], and with an increase in risk similar to that of conventional adenomas [37]. A lack of consistent recording by endoscopists in the era of this study precluded an examination of the separate impact of serrated lesions on proximal colon cancer incidence. Therefore, a proportion of the observed cancers in the proximal colon may have resulted from the development of serrated polyps, which were not detected or reported during baseline colonoscopy. The impact of serrated polyps in the proximal colon deserves further exploration to disentangle the effect of these polyps on proximal colon cancer incidence compared to adenomas.

Villousness is considered a criterion for colonoscopy surveillance in US guidance based on 'moderate' evidence of an association with CRC [15]. However, in the UK, due to inconsistencies in the classification of adenoma histology between pathologists, the strength of the evidence was not considered sufficient to support the increased resources which would be required for surveillance [14].

UK and US post-polypectomy surveillance guidelines [14, 15] do not consider adenoma location as an independent criterion for referral for surveillance, with patients either receiving no surveillance (UK) [14] or surveillance 7-10 years (US) [15] after baseline if no other high-risk adenoma characteristics (based on number, size, histology or dysplasia) are detected at baseline. This decision was based on a lack of consistent evidence to support differential management of patients with proximal adenomas [14, 15] and underpinned the recommendation for more research to determine whether these patients should be referred for surveillance [15]. In this UK cohort, the median time to diagnosis in patients with only proximal adenomas was 7 years but this was based on small numbers and should be interpreted with caution. Secondary analyses examining patients at high-risk (according to UK surveillance criteria) showed that adenoma number, histology and location were still independently associated with proximal colon cancer even after accounting for high-risk findings. However, as noted earlier, at the time of this study there was a lack of consistent reporting of serrated polyps, which are included as criteria for the classification of high-risk findings and which are thought to be important in proximal colon cancer development specifically.

This present study, in a cohort of patients followed up after a colonoscopy with polypectomy, has found that proximal location of adenomas, independent of number, size, histology or dysplasia (factors on which current guidelines are based), plays an important role in subsequent proximal colon cancer incidence. It supports previous analyses in this data reporting an increased risk of all-site CRC among patients with proximal polyps at baseline and adds to the growing body of research examining heterogeneity in risk factors for CRC by subsite. In addition, it provides much-needed insight into the specific adenoma risk factors for proximal colon cancer, a malignancy for which screening and surveillance have been less effective at reducing incidence.

DATA AVAILABILITY

We may be permitted to share de-identified patient data with researchers upon reasonable request, but this will require approval from third party data providers. Requests for data should be directed to the senior author of this manuscript, Professor Amanda Cross, Cancer Screening and Prevention Research Group, Imperial College London.

REFERENCES

- Cottet V, Jooste V, Fournel I, Bouvier AM, Faivre J, Bonithon-Kopp C. Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study. Gut. 2012;61:1180–6.
- Brenner H, Chang-Claude J, Jansen L, Seiler CM, Hoffmeister M. Role of colonoscopy and polyp characteristics in colorectal cancer after colonoscopic polyp detection: a population-based case-control study. Ann Intern Med. 2012;157:225–32.
- Pohl H, Robertson DJ, Mott LA, Ahnen DJ, Burke CA, Barry EL, et al. Association between adenoma location and risk of recurrence. Gastrointest Endosc. 2016;84:709–16.
- Martinez ME, Sampliner R, Marshall JR, Bhattacharyya AK, Reid ME, Alberts DS. Adenoma characteristics as risk factors for recurrence of advanced adenomas. Gastroenterology. 2001;120:1077–83.
- Saini SD, Kim HM, Schoenfeld P. Incidence of advanced adenomas at surveillance colonoscopy in patients with a personal history of colon adenomas: a metaanalysis and systematic review. Gastrointest Endosc. 2006;64:614–26.
- Laiyemo AO, Murphy G, Albert PS, Sansbury LB, Wang Z, Cross AJ, et al. Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years. Ann Intern Med. 2008;148:419–26.
- Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095–105.
- le Clercq CMC, Bouwens MWE, Rondagh EJA, Bakker CM, Keulen ETP, de Ridder RJ, et al. Postcolonoscopy colorectal cancers are preventable: a population-based study. Gut. 2014;63:957–63.
- Singh S, Singh PP, Murad MH, Singh H, Samadder NJ. Prevalence, risk factors, and outcomes of interval colorectal cancers: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1375–89.
- Cross AJ, Robbins EC, Pack K, Stenson I, Kirby PL, Patel B, et al. Long-term colorectal cancer incidence after adenoma removal and the effects of surveillance on incidence: a multicentre, retrospective, cohort study. Gut. 2020.69(9):1645-1658. https://doi.org/10.1136/gutjnl-2019-320036.
- 11. Fairley KJ, Li J, Komar M, Steigerwalt N, Erlich P. Predicting the risk of recurrent adenoma and incident colorectal cancer based on findings of the baseline colonoscopy. Clin Transl Gastroenterol. 2014;5:e64.
- He X, Hang D, Wu K, Nayor J, Drew DA, Giovannucci EL, et al. Long-term risk of colorectal cancer after removal of conventional adenomas and serrated polyps. Gastroenterology. 2020;158:852–61.e4.
- Wieszczy P, Kaminski MF, Franczyk R, Loberg M, Kobiela J, Rupinska M, et al. Colorectal cancer incidence and mortality after removal of adenomas during screening colonoscopies. Gastroenterology. 2020;158:875.
- Rutter MD, East J, Rees CJ, Cripps N, Docherty J, Dolwani S, et al. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/ Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines. Gut. 2020;69:201.
- Gupta S, Lieberman D, Anderson JC, Burke CA, Dominitz JA, Kaltenbach T, et al. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2020;158:1131–53 e5.
- Hassan C, Antonelli G, Dumonceau JM, Regula J, Bretthauer M, Chaussade S, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020. Endoscopy. 2020;52:687–700.
- Baran B, Ozupek NM, Tetik NY, Acar E, Bekcioglu O, Baskin Y. Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterol Res. 2018;11:264–73.
- Lee GH, Malietzis G, Askari A, Bernardo D, Al-Hassi HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? A systematic review. Eur J Surg Onc. 2015;41:300–8.
- 19. lacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101:403–8.
- Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med. 2011;154:22–U156.
- Lakoff J, Paszat LF, Saskin R, Rabeneck L. Risk of developing proximal versus distal colorectal cancer after a negative colonoscopy: a population-based study. Clin Gastroenterol Hepatol. 2008;6:1117–21.

- 23. Atkin W, Brenner A, Martin J, Wooldrage K, Shah U, Lucas F, et al. The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations. Health Technol Assess. 2017;21:1–536.
- 24. Atkin W, Wooldrage K, Brenner A, Martin J, Shah U, Perera S, et al. Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study. Lancet Oncol. 2017;18:823–34.
- Atkin WS, Saunders BP. British Society for G, Association of Coloproctology for Great B, Ireland. Surveillance guidelines after removal of colorectal adenomatous polyps. Gut. 2002;51:V6–9.
- Xue X, Kim MY, Gaudet MM, Park Y, Heo M, Hollenbeck AR, et al. A comparison of the polytomous logistic regression and joint cox proportional hazards models for evaluating multiple disease subtypes in prospective cohort studies. Cancer Epidemiol Biomark Prev. 2013;22:275–85.
- 27. StataCorp. STATA statistical software. 13.1 ed. College Station: Stata Corporation; 2016.
- Noshirwani KC, van Stolk RU, Rybicki LA, Beck GJ. Adenoma size and number are predictive of adenoma recurrence: implications for surveillance colonoscopy. Gastrointest Endosc. 2000;51:433–7.
- Laiyemo AO, Doubeni C, Sanderson AK 2nd, Pinsky PF, Badurdeen DS, Doria-Rose VP, et al. Likelihood of missed and recurrent adenomas in the proximal versus the distal colon. Gastrointest Endosc. 2011;74:253–61.
- Rex DK, Schoenfeld PS, Cohen J, Pike IM, Adler DG, Fennerty MB, et al. Quality indicators for colonoscopy. Gastrointest Endosc. 2015;81:31–53.
- 31. Valori R. Quality improvements in Endoscopy in England. Tech Gastrointest Endosc. 2012;14:63–72.
- East JE, Vieth M, Rex DK. Serrated lesions in colorectal cancer screening: detection, resection, pathology and surveillance. Gut. 2015;64:991–1000.
- East JE, Atkin WS, Bateman AC, Clark SK, Dolwani S, Ket SN, et al. British Society of Gastroenterology position statement on serrated polyps in the colon and rectum. Gut. 2017;66:1181–96.
- Huang CS, Farraye FA, Yang S, O'Brien MJ. The clinical significance of serrated polyps. Am J Gastroenterol. 2011;106:229–40. quiz 41.
- Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088–100.
- Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107:1315–29.
- Erichsen R, Baron JA, Hamilton-Dutoit SJ, Snover DC, Torlakovic EE, Pedersen L, et al. Increased risk of colorectal cancer development among patients with serrated polyps. Gastroenterology. 2016;150:895.

ACKNOWLEDGEMENTS

A special thank you to all the patients who contributed data to the study. We would like to acknowledge and thank those named as follows for their involvement. Cancer Screening and Prevention Research Group staff: Elizabeth Coles, Jain Stenson, Kevin Pack, Paula Kirby, Mariano Kalfors Perdices, Participating hospitals: Royal Sussex County Hospital, Brighton. Cumberland Infirmary, Carlisle. Imperial College Healthcare Trust: Charing Cross Hospital/Hammersmith Hospital and St Mary's Hospital, London. Glasgow Royal Infirmary, Glasgow. Leicester General Hospital, Leicester. Royal Liverpool University Hospital, Liverpool. New Cross Hospital, Wolverhampton. University Hospital of North Tees, Stockton-on-Tees. Queen Elizabeth Hospital, Woolwich, London. Queen Mary's Hospital, Sidcup, Kent. Royal Shrewsbury Hospital, Shropshire. St George's Hospital, Tooting, London. St Mark's Hospital, Harrow, London. Royal Surrey County Hospital, Surrey. Torbay District General Hospital, Devon. Yeovil District Hospital, Somerset. Data providers: NHS Digital, formerly the Health and Social Care Information Centre England (HSCIC). NHS Central Register and National Services Scotland (NSS) and the electronic Data Research and Innovation Service (eDRIS) team (NSS). This study includes data derived from patient-level information collected by the NHS, as part of the care and support of cancer patients. The data are collated, maintained and guality assured by the National Cancer Registration and Analysis Service of Public Health England (PHE) and access to the data was facilitated by the PHE Office for Data Release.

AUTHOR CONTRIBUTIONS

RH, KW and AJC conceived and designed the study. RH did the statistical analyses, interpreted the data and wrote the first draft of the manuscript. KW and AJC provided guidance on statistical analysis and data interpretation. All authors critically reviewed the manuscript for important intellectual content and approved the final version for publication. AJC acquired the funding for the study.

FUNDING

Cancer Research UK PhD studentship (reference C24523/A25192), National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (reference NIHR-HTA 15/80/13), the Bobby Moore Fund for Cancer Research UK (reference C8171/A16894) and the Cancer Research UK Population Research Committee Programme Award (reference C53889/A25004).

COMPETING INTERESTS

JK reports grants from H2020—Innovative Training Networks (ITN) grant, National Institute of Health Research (NIHR)—i4i grant, Cancer Research UK fellowship and Johnson and Johnson Educational grant, consultancy fees from Verb robotics/ Ethicon, LNC therapeutics, UDX diagnostics, speaker fees from Yakult, Johnson and Johnson and shares in Cerulean health, One Welbeck day surgery and Mangetoo. com. The remaining authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The Royal Free Research Ethics Committee (REC) granted approval for the original 'Intermediate Adenoma' study (REC reference 06/Q0501/45). Further ethics approval was granted for the subsequent 'All Adenomas' study by the London—Hampstead Research Ethics Committee (REC) and Health Research Authority in May 2017 (IRAS reference 55943, REC reference 06/Q0501/45). Approval for the processing of patient identifiable information without consent was originally granted by the Patient Information Advisory Group (PIAG) under Section 60 of the Health and Social Care Act 2001 (re-enacted by Section 251 of the NHS Act 2006) and subsequent updates were approved by the HRA-Confidentiality Advisory Group (reference PIAG 1–05[e]/2006).

CONSENT FOR PUBLICATION

Not applicable

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41416-022-01719-4.

Correspondence and requests for materials should be addressed to Rhea Harewood.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.

© The Author(s) 2022